Smartleaf Asset Management’s Rigel Pharmaceuticals RIGL Stock Holding History

Smartleaf Asset Management’s Portfolio RIGL Stock Details RIGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$2.64K	Buy	+54	New	+$2.34K	﹤0.01%	2955

Other funds holding RIGL

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

American Century Companies Kansas City, Missouri $229B AUM 33.35% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $54.1B AUM 39.29% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return

Marshall Wace London, United Kingdom $114B AUM 35.47% 1-Year Est. Return

Smartleaf Asset Management's RIGL Position: Q3 2026 in Review

Smartleaf Asset Management opened a new position in Rigel Pharmaceuticals (RIGL) in Q3 2026: 54 shares worth $2.64K. The stake represents ﹤0.01% of the portfolio and ranks #2955 among its holdings.

127 funds tracked by Wall St. Rank hold RIGL as of Q3 2026.

Smartleaf Asset Management held 54 shares of Rigel Pharmaceuticals worth $2.64K as of Q3 2026.
Rigel Pharmaceuticals was a new Smartleaf Asset Management position in Q3 2026.
Rigel Pharmaceuticals made up ﹤0.01% of Smartleaf Asset Management's portfolio in Q3 2026, its #2955 holding.
127 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q3 2026.

Based on Smartleaf Asset Management's 13F filing for Q3 2026, filed 10 Nov 2026.